Dr. Maddocks on Ongoing Sequencing Challenges in DLBCL

Supplements And Featured Publications, Year in Review: Updates in DLBCL Treatment, Volume 1, Issue 1

In Partnership With:

Partner | Cancer Centers | <b>The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James)</b>

Kami J. Maddocks, MD, discusses ongoing sequencing challenges in diffuse large B-cell lymphoma.

Kami J. Maddocks, MD, an associate professor of clinical internal medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center–James, discusses ongoing sequencing challenges in diffuse large B-cell lymphoma (DLBCL).

As more therapies are approved for the treatment of patients with DLBCL, sequencing challenges continue to arise, Maddocks explains.

For example, the question of whether CAR T-cell therapies can be moved into earlier lines of treatment for patients with high-risk disease or who are not candidates for autologous stem cell transplant remains unanswered, Maddocks says.

Additionally, the recently approved CD19-directed monoclonal antibody tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid), as well as other CD19-directed therapies under investigation, may have efficacy earlier on in treatment or for patients who progress after CAR T-cell therapy, says Maddocks.

Other therapies such as polatuzumab vedotin (Polivy) in combination with bendamustine and rituximab (Rituxan; BR) and selinexor (Xpovio) are currently approved for the treatment of patients who have received at least 2 prior therapies. However, the optimal role of these agents has yet to be determined, concludes Maddocks.